Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/26490
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Goossens, Maria E. | - |
dc.contributor.author | Zeegers, Maurice P. | - |
dc.contributor.author | van Poppel, Hendrik | - |
dc.contributor.author | Joniau, Steven | - |
dc.contributor.author | Ackaert, Koen | - |
dc.contributor.author | Ameye, Filip | - |
dc.contributor.author | Billiet, Ignace | - |
dc.contributor.author | Braeckman, Johan | - |
dc.contributor.author | Breugelmans, Alex | - |
dc.contributor.author | Darras, Jochen | - |
dc.contributor.author | DILEN, Kurt | - |
dc.contributor.author | Goeman, Lieven | - |
dc.contributor.author | Tombal, Bertrand | - |
dc.contributor.author | Van Bruwaene, Siska | - |
dc.contributor.author | Van Cleyenbreugel, Ben | - |
dc.contributor.author | Van der Aa, Frank | - |
dc.contributor.author | VEKEMANS, Kristiaan | - |
dc.contributor.author | Buntinx, Frank | - |
dc.date.accessioned | 2018-07-31T08:07:06Z | - |
dc.date.available | 2018-07-31T08:07:06Z | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | EUROPEAN JOURNAL OF CANCER, 69, p. 9-18 | - |
dc.identifier.issn | 0959-8049 | - |
dc.identifier.uri | http://hdl.handle.net/1942/26490 | - |
dc.description.abstract | Background: In Belgium, bladder cancer (BC) is the fifth most common cancer in men. The per-patient lifetime cost is high. Previous epidemiological studies have consistently reported that selenium concentrations were inversely associated with the risk of BC. We therefore hypothesised that selenium may be suitable for chemoprevention of recurrence of BC. Method: The Selenium and Bladder Cancer Trial (SELEBLAT) was an academic phase III placebo-controlled, double-blind, randomised clinical trial designed to determine the effect of selenium on recurrence of non-invasive urothelial carcinoma conducted in 14 Belgian hospitals. Patients were randomly assigned by a computer program to oral selenium yeast 200 mu g once a day or placebo for three years, in addition to standard care. All study personnel and participants were blinded to treatment assignment for the duration of the study. All randomised patients were included in the intention to treat (ITT) and safety analyses. Per protocol analyses (PPAs) included all patients in the study three months after start date. Results: Between September 18, 2009 and April 18, 2013, 151 and 141 patients were randomised in the selenium and placebo group. Patients were followed until December 31, 2015. The ITT analysis resulted in 43 (28%; 95% CI, 0.21-0.35) and 45 (32%; 95% CI, 0.24-0.40) recurrences in the selenium and placebo group. The hazard ratio (HR) was 0.85 (95% CI, 0.56-1.29; p = 0.44) while the HR for the PPA resulted in 42 and 39 (28%; 95% CI, 0.20-0.35) recurrences in the selenium and placebo group (HR = 0.96 [95% CI, 0.62 -1.48]; p = 0.93). Conclusion: Selenium supplementation does not lower the probability of recurrence in BC patients. (C) 2016 Elsevier Ltd. All rights reserved. | - |
dc.description.sponsorship | The SELEBLAT study was funded by an unconditional grant of the Agency for Innovation by Science and Technology Belgium (IWT) (project IWT 70699). The funder of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report. Drugs were supplied by PharmaNord, Vojens, Denmark and prepared according to the principles of good manufacturing practice (GMP). The authors acknowledge all participating urologists from the 14 recruiting hospitals for their willingness to participate in the SELEBLAT study. The authors recognize the invaluable contribution made by the research nurses and administrative staff. The authors also acknowledge the members of the data and safety monitoring board and the staff of the Vesalius Research Centrum. | - |
dc.language.iso | en | - |
dc.rights | (C) 2016 Elsevier Ltd. All rights reserved. | - |
dc.subject.other | selenium; bladder cancer; non-invasive urothelial carcinoma; transitional cell carcinoma; chemoprevention; randomised clinical trial; urology | - |
dc.title | Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 18 | - |
dc.identifier.spage | 9 | - |
dc.identifier.volume | 69 | - |
local.bibliographicCitation.jcat | A1 | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
local.class | dsPublValOverrule/internal_author_not_expected | - |
local.class | IncludeIn-ExcludeFrom-List/ExcludeFromFRIS | - |
dc.identifier.doi | 10.1016/j.ejca.2016.09.021 | - |
dc.identifier.isi | 000388846300002 | - |
item.fullcitation | Goossens, Maria E.; Zeegers, Maurice P.; van Poppel, Hendrik; Joniau, Steven; Ackaert, Koen; Ameye, Filip; Billiet, Ignace; Braeckman, Johan; Breugelmans, Alex; Darras, Jochen; DILEN, Kurt; Goeman, Lieven; Tombal, Bertrand; Van Bruwaene, Siska; Van Cleyenbreugel, Ben; Van der Aa, Frank; VEKEMANS, Kristiaan & Buntinx, Frank (2016) Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial. In: EUROPEAN JOURNAL OF CANCER, 69, p. 9-18. | - |
item.fulltext | With Fulltext | - |
item.contributor | Goossens, Maria E. | - |
item.contributor | Zeegers, Maurice P. | - |
item.contributor | van Poppel, Hendrik | - |
item.contributor | Joniau, Steven | - |
item.contributor | Ackaert, Koen | - |
item.contributor | Ameye, Filip | - |
item.contributor | Billiet, Ignace | - |
item.contributor | Braeckman, Johan | - |
item.contributor | Breugelmans, Alex | - |
item.contributor | Darras, Jochen | - |
item.contributor | DILEN, Kurt | - |
item.contributor | Goeman, Lieven | - |
item.contributor | Tombal, Bertrand | - |
item.contributor | Van Bruwaene, Siska | - |
item.contributor | Van Cleyenbreugel, Ben | - |
item.contributor | Van der Aa, Frank | - |
item.contributor | VEKEMANS, Kristiaan | - |
item.contributor | Buntinx, Frank | - |
item.accessRights | Restricted Access | - |
crisitem.journal.issn | 0959-8049 | - |
crisitem.journal.eissn | 1879-0852 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Goosens.pdf Restricted Access | Published version | 714.83 kB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
11
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
17
checked on Sep 26, 2024
Page view(s)
86
checked on Sep 7, 2022
Download(s)
60
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.